Tscan Therapeutics is trading at $0.78 (+5.10%) as part of a broader market rebound, with no company-specific announcements, earnings updates, or analyst actions identified.
- The move aligns with a general risk-on sentiment in U.S. equities, supported by a 2.62% gain in the Nasdaq Composite.
- Recent price action suggests the stock is recovering alongside other small-cap biotech firms following broader market strength.